Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography

Joost R. C. Lameijer1 · Angela MP Coolen2 · Adri C. Voogd3,4,5 · Luc J. Strobbe6 · Marieke W. J. Louwman4 · Dick Venderink6 · Vivian C. Tjan-Heijnen5 · Lucien E. M. Duijm6,7

Abstract

Purpose To determine the frequency and characteristics of contralateral, non-recalled breast abnormalities following recall at screening mammography.

Methods We included a series of 130,338 screening mammograms performed between 1 January 2014 and 1 January 2016. During the 1-year follow-up, clinical data were collected for all recalls. Screening outcome was determined for recalled women with or without evaluation of contralateral breast abnormalities.

Results Of 3,995 recalls (recall rate 3.1%), 129 women (3.2%) underwent assessment of a contralateral, non-recalled breast abnormality. Most lesions were detected at clinical mammography and/or breast tomosynthesis (101 women, 78.3%). The biopsy rate was similar for recalled lesions and contralateral, non-recalled lesions, but the positive predictive value of biopsy was higher for recalled lesions ($p = 0.01$). A comparable proportion of the recalled lesions and contralateral, non-recalled lesions were malignant ($p = 0.1$). The proportion of ductal carcinoma in situ was similar for both groups, as well as invasive cancer characteristics and type of surgical treatment.

Conclusions About 3% of recalled women underwent evaluation of contralateral, non-recalled breast lesions. Evaluation of the contralateral breast after recall is important as we found that 15.5% of contralateral, non-recalled lesions were malignant. Contralateral cancers and screen-detected cancers show similar characteristics, stage and surgical treatment.

Key Points

- 3% of recalled women underwent evaluation of contralateral, non-recalled lesions
- One out of seven contralateral, non-recalled lesions was malignant
- A contralateral cancer was diagnosed in 0.5% of recalls
- Screen-detected cancers and non-recalled, contralateral cancers showed similar histological characteristics
- Tumour stage and surgical treatment were similar for both groups

Keywords Mammography · Mass screening · Breast neoplasms · Breast · Radiology

Abbreviations

- CNB Core-needle biopsy
- DBT Digital breast tomosynthesis
- FFDM Full-field digital mammography
- FNAC Fine-needle aspiration cytology
- SCNB Stereotactic core needle biopsy

1 Department of Radiology, Catharina Hospital, Michelangelolaan 2, 5623EJ, Eindhoven, The Netherlands
2 Department of Radiology, Elisabeth-Tweesteden Hospital (ETZ), Hilvarenbeekseweg 60, 5022 GC Tilburg, The Netherlands
3 Department of Epidemiology, Maastricht University, P Debyelaan 1, 6229 HA Maastricht, The Netherlands
4 Department of Research, Netherlands Comprehensive Cancer Organization (iKNL), PO Box 19079, 3501 DB Utrecht, The Netherlands
5 Department of Internal Medicine, Division of Medical Oncology, GROW Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands
6 Department of Radiology, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands
7 Dutch Expert Centre for Screening, PO Box 6873, 6503 GJ Nijmegen, The Netherlands
Introduction

Many countries have introduced breast cancer screening programmes with the aim to detect breast cancers at an early stage, before they grow large enough to become symptomatic, and thus to decrease morbidity and improve breast cancer survival. Breast cancer mortality has decreased in the past 20 years in The Netherlands and this improved survival is due to a combination of breast cancer screening and improved treatment [1–3].

Breast cancers detected at screening are often small and non-symptomatic. Improved radiological breast imaging techniques, including the replacement of screen-film mammography by full-field digital mammography (FFDM) and the recent introduction of breast tomosynthesis (three-dimensional mammography), have resulted in a more accurate detection and characterisation of breast lesions at screening mammography [4, 5]. Breast tomosynthesis has not yet been implemented in our nation-wide screening mammography programme. Women are usually recalled for a unilateral lesion at screening mammography, but a small percentage of cases (1-2%) is recalled for suspicious bilateral lesions [6].

After recall, additional breast imaging is performed for the evaluation of the suspected lesion detected at screening mammography. In a diagnostic setting, the addition of breast tomosynthesis to digital mammography results in a higher sensitivity and specificity of breast cancer diagnosis than digital mammography alone [7–9]. For example, Gilbert et al. [9] reported a higher sensitivity for the detection of invasive cancers sized 11-20 mm when adding tomosynthesis to digital mammography in a diagnostic setting (93% versus 86%, \( p < 0.001 \)). Specificity also increased, from 58% with digital mammography to 69% with digital mammography plus breast tomosynthesis. Lång et al. [10] found an increased lesion visualisation with breast tomosynthesis compared to digital mammography, especially for spiculated masses.

Additional breast cancers may be detected in the breast for which the woman has been recalled, or in the contralateral breast. Preoperative breast magnetic resonance imaging (MRI) in breast cancer patients has also been shown to detect additional malignancies in one or both breasts in a significant number of patients, and the MRI findings frequently result in more extensive surgery compared to the initially proposed treatment, such as additional contralateral mastectomy [11–13].

To our knowledge, no previous studies have reported on additionally detected contralateral breast lesions in women recalled for a unilateral abnormality at screening mammography. We, therefore, assessed the frequency and characteristics of these contralateral lesions in women who attended a biennial screening mammogram programme in the South of The Netherlands.

Materials and methods

Study design and study population

This is a prospective observational follow-up study of women aged 50-75 who attended a biennial breast cancer screening programme conducted in the south of The Netherlands. A consecutive series of 130,338 full-field digital mammography screens (13,762 initial screens and 116,576 subsequent screens) between 1 January 2014 and 1 January 2016 were included. The screening mammograms were obtained at four specialised screening units in a biennial screening mammography programme conducted in the south of The Netherlands.

Women are personally invited by letter to attend the screening programme. These letters are sent to the address of every woman aged between 50 and 75 years old registered in the municipal registration. Women being treated for breast cancer or those attending clinical follow-up after treatment of breast cancer do not attend the screening programme. Otherwise, there are no exclusion criteria for screening eligibility.

Women participating in our screening mammography programme were asked for permission to use their data for scientific purposes and for the evaluation of the screening programme. All women gave permission to use their screening and diagnostic data.

Possible exclusion criteria included no permission to use screen data, technical failure of screening equipment and insufficient image quality as assessed by an experienced screening radiologist. None of the women screened for study inclusion met these criteria.

A total of 3,995 women were recalled for further analysis. The hospitals involved in these recalls were visited and data as described below were obtained. Possible exclusion criteria after recall included insufficient follow-up or loss to follow-up, incomplete records, no permission to access data. None of the women recalled for analysis met these criteria and no recalls were excluded from analysis.

Ethical approval by our local Institutional Review Board was not required for this prospective observational follow-up study, according to the Dutch Central Committee on Research involving Human Subjects (CCMO).

Screening procedure and recall

Details of our breast cancer screening programme have been described previously [14]. In brief, the mammography screening programme in The Netherlands is a nationwide programme that provides free biennial screening mammography for women aged 50-75 years. Women are personally invited for screening and the attendance rate is more than 80%. Before each screening examination, the woman completes a short questionnaire with questions about previous recalls and any previous breast surgery or breast malignancy.
All digital mammograms were obtained with a Lord Selenia FFDM system (Hologic, Danbury, CT, USA), with a 70-μm pixel size and a 232 × 286-mm field of view. The examinations were obtained by specialised screening mammography radiographers and all screening mammograms were double-read in a blinded fashion by a team of 12 certified screening radiologists. Each radiologist evaluated at least 3,000 mammograms yearly.

The screening radiologists classified abnormal mammographic findings into one of the following categories: suspicious mass, suspicious calcifications, suspicious mass in combination with calcifications, architectural distortion, asymmetry or other. Each screen was then classified according to the BI-RADS lexicon [15]. Women with a BI-RADS 1 or 2 were not recalled and women with a BI-RADS 0, 4 or 5 were referred to a dedicated breast unit of a hospital for further analysis of their mammographic finding. The BI-RADS category 3 is not applied as short-term follow-up is not available in the Dutch screening programme.

Diagnostic work-up after recall

Although a total of 20 hospitals were involved in the diagnostic work-up of recalled women, the diagnostic work-up in the majority of women (97.2%, 3,883/3,995) was performed in seven regional hospitals. All recalled women underwent physical examination by a surgical oncologist or dedicated breast nurse and received additional evaluation at the radiology department. A radiologist first reassessed the screening mammogram of both breasts, which was routinely available and stored in the Picture Archiving and Communication System (PACS) of the hospital. Additional imaging was obtained at the discretion of the radiologist after this review. Full-field digital mammography was available in each of the seven regional hospitals. Breast tomosynthesis was present in two hospitals from the beginning of the inclusion period and became available in three others in 2015. Breast ultrasonography was used for the further characterisation of mammographic abnormalities and palpable breast lesions, for biopsy guidance and for target or second look purposes following breast MRI. Whole-breast ultrasonography was not encouraged, in accordance with the Dutch guidelines [16]. Breast MRI was also available in each of the seven hospitals and performed if indicated, as defined by the guidelines of the European Society of Breast Imaging [17] and the Dutch guidelines. Fine-needle aspiration biopsy (FNAB), core-needle biopsy (CNB) and stereotactic biopsy were performed in each of the seven hospitals, whereas MRI guided biopsy procedures were concentrated in the larger hospitals. All recalls were discussed by multidisciplinary teams that consisted of surgical oncologists, radiologists, medical oncologists, radiation oncologists, plastic surgeons, breast nurses and breast radiographers.

During 1-year follow-up, clinical data and data from diagnostic breast imaging, biopsy specimen and surgical procedures were collected of all recalled women. Information on breast density, hormonal replacement therapy and family history of breast cancer were also extracted from the screening records and clinical data. Breast cancers were categorised into ductal carcinoma in situ (DCIS) and invasive cancers; lobular carcinoma in situ was considered a non-malignant lesion. The TNM (tumour, nodes and metastases) classification was used for malignant lesions [18]. For all cancers treated by neoadjuvant therapy (either chemotherapy or anti-hormonal therapy), tumour size was derived from breast imaging (usually MRI) prior to the start of this therapy.

Detection and assessment of contralateral breast lesions

The methods of detection and subsequent assessment of contralateral breast lesions were derived from the clinical records and clinical radiology reports. Similar to the work-up of screen-detected mammographic abnormalities, biopsy data and surgical reports of contralateral breast lesions were obtained.

Two screening radiologists reviewed the latest screening mammogram of each woman with a cancer diagnosed in the contralateral breast. They classified the cancer as missed, minimal sign or occult at the previous screen according to the European guidelines [19, 20].

Statistical analysis, missing data and bias

Descriptive statistics were performed using Statistical Package for Social Science 23.0 (SPSS IBM, Chicago, IL, USA). The chi-squared test was used to test for differences between women without and with additional contralateral breast lesions detected following recall. A $p$ value of less than 0.05 was considered to indicate a statistically significant difference. The $p$ values were two sided.

There was no loss to follow-up. In a small number of cases, data were missing (e.g. oestrogen or progesterone receptor status missing due to an insufficient tissue sample). Statistical correction was not performed for the very small numbers of missing data, and data missing was considered to be at random.

Bias was not expected in recall of women who attended screening. In the diagnostic setting, several types of bias may occur, especially observer bias and detection bias, but statistical correction for this type of bias is not feasible in this study. Selection bias was considered highly unlikely as all women analysed in the diagnostic setting were included for statistical analysis.
Results

Overall screening results

The mean age of the 130,338 consecutively screened women was 59.6 years (95% CI, 59.4–59.8 years) and 8.2% reported to have had previous breast surgery. A total of 3,995 (3.1%) were recalled for further assessment. Breast cancer was diagnosed in 905 recalled women [including 163 (18.0%) ductal carcinoma in situ], resulting in an overall cancer detection rate of 6.9 per 1,000 screens [initial screens, 8.6 (118/13,762); subsequent screens, 6.8 (787/116,576)] and an overall positive predictive value (PPV) of recall of 22.7% [initial screens, 11.4% (118/1,037); subsequent screens, 26.6% (787/2,958)]. A patient flow chart is provided in Fig. 1.

Detection of contralateral lesions

A total of 129 women, 3.2% of all recalls, underwent assessment of a contralateral breast abnormality that was detected after recall. Baseline characteristics of recalled women, with or without analysis of a contralateral non-recalled lesion, are shown in Table 1. These characteristics were similar for both groups except for a higher breast density (III + IV) in women assessed for a contralateral breast lesion when compared to a recalled breast lesion (38.8% and 23.8% respectively, p < 0.001).

The contralateral abnormality was detected at clinical mammography and/or breast tomosynthesis in 101 women and at breast MRI in 23 women. In the remaining five women, the contralateral breast was evaluated due to the presence of a suspicious finding at clinical breast examination by the surgical oncologist or breast nurse (palpable breast lesion, four cases; Paget disease of the nipple, one case).

Table 1: Baseline characteristics of recalled women

|                        | No contralateral lesions | Contralateral lesions | p value |
|------------------------|--------------------------|-----------------------|---------|
| Mean age, years (95% CI) | 59.1 (58.8–59.4)         | 58.4 (57.1–59.8)     | 0.35    |
| Screening round, No (%)  |                          |                       |         |
| Initial                | 996 (25.8)               | 41 (31.8)             | 0.13    |
| Subsequent             | 2,870 (74.2)             | 88 (68.2)             |         |
| Breast density, No (%)  |                          |                       | <0.001  |
| I + II (<50%)          | 2,946 (76.2)             | 79 (61.2)             |         |
| III + IV (>50%)        | 920 (23.8)               | 50 (38.8)             |         |
| Previous breast surgery, No (%) |          |                       | 0.69    |
| Yes                    | 322 (8.3)                | 12 (9.3)              |         |
| No                     | 3,544 (91.7)             | 117 (90.7)            |         |
| Hormone replacement therapy, No (%) |          |                       | 0.11    |
| Yes                    | 159 (4.1)                | 9 (7.0)               |         |
| No                     | 3,707 (95.9)             | 120 (93.0)            |         |
| Family history of breast cancer, No (%) |          |                       | 0.61    |
| Yes                    | 509 (13.2)               | 19 (14.7)             |         |
| No                     | 3,357 (86.8)             | 110 (85.3)            |         |

The mammographic characteristics of the contralateral lesions detected at clinical mammography (with/without tomosynthesis) were as follows: suspicious mass, 90; suspicious calcifications, 8; suspicious mass with calcifications, 1; architectural distortion, 2. The indications for breast MRI in the 23 women with a contralateral lesion detected at MRI had been as follows: problem solving of the recalled lesion, 9 women; determination of tumour size and/or multifocality/multicentricity of a screen detected malignancy, 10 women; invasive lobular cancer, 4 women. Breast MRI showed a suspicious mass or non-mass enhancement in 19 women and 4 women, respectively.

Work-up of lesions detected in the contralateral breast

The majority of women with an abnormality detected in the contralateral breast underwent only breast imaging for the

Table 2: Work-up of lesions detected in the contralateral breast during recall

|                        | No (%) |
|------------------------|--------|
| Breast ultrasonography, No (%) | 74 (57.4) |
| Breast ultrasonography plus biopsy, No (%) |        |
| FNAC                   | 1 (0.8) |
| CNB                    | 36 (27.9) |
| SCNB                   | 10 (7.8) |
| FNAC + CNB             | 1 (0.8) |
| CNB + SCNB             | 2 (1.6) |
| Percutaneous biopsy + excisional biopsy | 4 (3.1) |
| Excisional biopsy       | 1 (0.8) |

FNAC fine-needle aspiration cytology, CNB core-needle biopsy, SCNB stereotactic core-needle biopsy
further evaluation of these lesions (Table 2). A total of 74 women (57.4%) received breast ultrasonography and the remaining 55 women (42.6%) underwent one or several percutaneous and/or excisional biopsy procedures to establish a final pathological diagnosis.

Outcome of lesions detected in the contralateral breast

Of the 129 lesions detected in the contralateral breast, 20 (15.5%) proved to be malignant (Table 3). The majority of the malignancies presented themselves as a suspicious mass at clinical mammography (eight cases, 47.1%) or breast MRI (seven cases, 41.2%). Of the nine contralateral breast cancers detected at mammography, two were visible only at breast tomosynthesis and not at the full-field digital mammogram. Of the seven cancers visible at the latest screening mammogram in retrospect, respectively four were considered to be missed and three showed a minimal sign. As mentioned previously, the remaining three contralateral cancers presented as palpable breast lesions, not primarily detected at breast imaging. In 16 of the 20 women with a breast cancer diagnosed in the contralateral breast, the mammographic abnormality at screening turned out to be malignant as well, resulting in 16 bilateral cancer cases. In the four remaining cases, the contralateral lesion turned out to be malignant, and the mammographic abnormality at screening turned out to be benign. One of these cases is presented in Fig. 2. The majority of benign lesions detected in the contralateral breast comprised cysts (52.3%, 57/109) and fibroadenomas (13.8%, 15/109).

Comparison of unilateral, screen-detected abnormalities with those detected in the contralateral, non-recalled breast

Of the recalled lesions and contralateral, non-recalled lesions, respectively 22.6% and 15.5% proved to be malignant ($p = 0.06$; Table 4). The type of assessment after recall (clinical breast imaging versus biopsy in addition to clinical breast imaging) was similar for both groups. The positive predictive value of biopsy, however, was higher for recalled lesions (53.1% vs 36.4%, $p = 0.01$). The tumour characteristics and final surgical treatment of unilateral, screen-detected cancers were similar with those of cancers diagnosed in the contralateral, non-recalled breast (Table 5).

---

### Table 3 Characteristics and outcome of lesions in the contralateral breast, detected at clinical breast imaging following recall

| Detection method and radiological abnormality, No (%) | Benign | Malignant |
|------------------------------------------------------|--------|-----------|
| Mammographya | | |
| Suspicious mass | 81 (65.2) | 6 (35.3) |
| Suspicious calcifications | 8 (6.5) | 1 (5.9) |
| Suspicious mass with calcifications | 1 (0.8) | 0 |
| Architectural distortion | 2 (1.6) | 0 |
| Tomosynthesis-only | | |
| Suspicious mass | 9 (7.3) | 2 (11.8) |
| Breast MRI | | |
| Suspicious mass | 19 (15.3) | 7 (41.2) |
| Focal non-mass enhancement | 4 (3.2) | 1 (5.9) |

a With or without breast tomosynthesis
Discussion

In the current study, we found that one out of 30 recalled women underwent analysis of a contralateral, non-recalled breast lesion and about one out of seven of these latter lesions proved to be malignant. The positive predictive value of biopsy of contralateral abnormalities, detected following recall, was lower than that of screen-detected lesions. Contralateral cancers and screen-detected cancers showed similar histological tumour characteristics, tumour stage and surgical treatment.

In retrospect, four out of 20 contralateral malignancies in our series were considered to be missed at the latest screening examination. Setz-Pels et al. [6] found that the sensitivity of screening mammography for the detection of bilateral breast cancer is less than 20%. The authors concluded that both screening radiologists and clinical radiologists should pay vigorous attention to the contralateral breast in order to detect bilateral malignancies without diagnostic delay. However, they do not provide information on the overall presence and work-up of contralateral, non-recalled breast abnormalities.

We found that 3.2% of recalled women underwent assessment of a contralateral, non-recalled breast abnormality. The majority of these lesions were detected at clinical mammography and/or breast tomosynthesis. Tomosynthesis is increasingly used, both at screening mammography and in a diagnostic setting. The addition of tomosynthesis to digital screening mammography may increase the cancer detection rate. A recent US study reported a decreased recall rate 3 years after the introduction of breast tomosynthesis (from 10.4 to 9.0%, \( p < 0.001 \)), as well as an increased positive predictive value of recall (from 4.4 to 6.7%, \( p = 0.02 \)) and a decreased interval cancer rate. A UK study found an increased specificity when adding tomosynthesis to digital screening mammography (70% versus 57%, \( p < 0.001 \)) and an increased sensitivity for cancer detection in dense breasts (93% versus 86%, \( p = 0.03 \)) [9, 21].

Tomosynthesis is not yet implemented in the Dutch screening mammography setting. An increasing number of hospitals have this modality at their disposal. In our series, two of the contralateral breast cancers were visible only at breast tomosynthesis and not at the full-field digital mammogram. It is likely that the intensified use of tomosynthesis in the work-up of recalled women will increase the number of lesions detected in contralateral, non-recalled breasts [7, 8]. A substantial number of contralateral lesions in our study were detected at breast MRI. Again, it can be expected that a further increase in the use of MRI, as well as the introduction of new and promising imaging modalities such as contrast-enhanced spectral mammography [22, 23], will increase the number of breast lesions detected in the contralateral breast of recalled women.

Additional percutaneous biopsy was performed in 43% of these lesions, with a lower positive predictive value of biopsy (36.4%) than the one observed for recalled lesions (53.1%, \( p < 0.01 \)). Excision biopsy, all with benign final pathology, was performed in five women. In some rare cases, excision biopsy may be necessary to establish a final diagnosis. Also, some women may desire excision of a benign lesion. Nevertheless, one should aim to minimise excision biopsy for diagnostic purposes as it has been shown that the sensitivity of screening...
mammography is lower in women after benign breast surgery [24].

We found no statistically significant differences in the proportions of malignancies among recalled lesions and contralateral, non-recalled malignant lesions (22.6% versus 15.5%). This study could be statistically underpowered to detect a clinically relevant difference due to small patient numbers. The observed trend of a lower cancer risk for contralateral lesions may be due to the fact that screening radiologists have no other tool than the screening mammogram and they have to keep recall percentages within acceptable limits. On the other hand, clinical radiologists are likely to have a lower threshold to exclude malignancy in mammographic lesions for which a woman has not been recalled.

Diagnosis of bilateral breast cancer was established in 16 of 20 women with a contralateral malignant lesions in the non-recalled breast, and four unilateral cancers were diagnosed in a breast for which a woman had not been recalled. A synchronous diagnosis of bilateral breast cancer may have an impact on the choice of final surgical therapy as these women are more inclined to opt for mastectomy over breast-conserving surgery [25]. The survival of patients with bilateral disease is likely to be worse than that of patients with unilateral disease [26, 27].

Studies have demonstrated an improved cancer detection when MRI or whole-breast ultrasound is added to mammography [12, 28, 29]. The increased sensitivity, however, is accompanied by an increase in false-positive findings. Moreover, enhanced use of MRI is correlated with an increase in mastectomy procedures [30–32]. Therefore, the guidelines of the European Society of Breast Imaging and the Dutch guidelines do not promote the standard use of MRI or whole-breast ultrasound in recalled women or in women with pathologically proven breast cancer [16, 17]. Breast ultrasonography should be used mainly as an evaluation tool of lesions detected at mammography or MRI (target ultrasonography or second look) and for the assessment of palpable breast lesions that are occult at mammography. Indications for breast MRI are screening of high risk women, screening of women with dense breasts, detection of additional ipsilateral and contralateral malignancies in invasive lobular cancer, determination of tumour size in dense breasts and in select cases for problem solving of lesions detected at mammography and/or breast ultrasonography.

Recalled women with or without assessment of a non-recalled, contralateral abnormality showed similar baseline characteristics except of a higher mammographic breast parenchyma density in the first group ($p < 0.001$). This may be explained by the fact that additional imaging modalities used in the clinical setting, as mentioned above, have a higher sensitivity for lesion detection compared to mammography, especially in dense breasts [10, 12, 29, 30, 33, 34].

It seems remarkable that three out of 20 detected contralateral malignancies were diagnosed by physical examination only. Contrary to a common perception that imaging obviates the need for physical examination, it remains a mainstay of diagnosis and an integral part of breast awareness and (self-)screening [35].

Tumour characteristics of cancers diagnosed in the contralateral, non-recalled breast were similar to those of unilateral, screen-detected cancers. A majority of cancers in both groups were of the invasive ductal type, stage T1, lymph node negative and grade I or II. A Dutch study found that contralateral breast cancers detected by screening comprised more lobular cancers and showed less nodal involvement than index cancers or unilateral cancers [6].

Our study has certain strengths and limitations. To our knowledge, we are the first to describe the frequency and characteristics of contralateral breast lesions following recall. The study population is large and recalled women were evaluated in multiple hospitals. Our results, however, may not be representative for other regional or nationwide screening mammography programmes as these programmes may show variations in screening interval (1-3 years), reading strategy

### Table 4

Overall screening outcome of recalled lesions versus lesions analysed in the contralateral, non-recalled breast

|                        | Recalled lesions* | Lesions assessed in the contralateral, non-recalled breast | $p$ value |
|------------------------|-------------------|----------------------------------------------------------|-----------|
| Screening outcome, No (%) | $n = 3,995$ | $n = 129$ | 0.06 |
| False positive | 3,094 (77.4) | 109 (84.5) | 0.06 |
| True positive | 901 (22.6) | 20 (15.5) | 0.06 |
| Type of assessment after recall, No (%) | 0.98 |
| Clinical breast imaging | 2,297 (57.5) | 74 (57.4) | 0.98 |
| Clinical breast imaging + biopsy | 1,698 (42.5) | 55 (42.6) | 0.98 |
| Positive predictive value of biopsy, % | 53.1 | 36.4 | 0.01 |

*Dominant mammographic abnormality in case of multiple recalled lesions
(single reading versus double reading), percentage of recalled women and availability of higher-end radiological equipment (e.g. tomosynthesis, stereotactic core-needle biopsy, 3-T MRI) at departments of radiology. Furthermore, as mentioned previously, the number of lesions detected in the contralateral breast may increase in the future as new techniques are increasingly implemented in the setting of clinical breast imaging. Ultimately, a majority of the women with contralateral breast lesions only underwent clinical breast imaging, without additional biopsy. BI-RADS 1 and BI-RADS 2 findings did not receive any radiological follow-up, whereas BI-RADS 3 lesions were either biopsied or received their first radiological follow-up at 6 months. As the follow-up period of all recalled women was 1 year, we cannot rule out that a contralateral lesion with benign follow-up may eventually turn out to be malignant.

In summary, reassessment of the complete screening mammogram, including the contralateral breast after recall, is important as contralateral cancers may be detected. We do not advocate a routine evaluation of the contralateral breast with additional imaging procedures following this reassessment, as this strategy will likely not be cost-effective. A timely diagnosis of the contralateral breast may be of influence on the choice of surgical therapy of a screen-detected cancer and survival.

**Funding** The Dutch Health Care Insurance Board finances and provides national coordination for the breast cancer screening programme.

### Table 5  Tumour characteristics of unilateral, screen-detected cancers versus cancers diagnosed in the contralateral, non-recalled breast

|                         | Unilateral SDCs (n = 901) | Contralateral cancers (n = 20) | p value |
|-------------------------|---------------------------|-------------------------------|---------|
| Type of cancer, No (%)  |                           |                               | 0.4     |
| DCIS                    | 162 (18.0)                | 2 (10.0)                      |         |
| Invasive                | 739 (82.0)                | 18 (90.0)                     |         |
| Histology of invasive cancers, No (%) |                     |                               | 0.2     |
| Ductal                  | 581 (78.6)                | 12 (66.7)                     |         |
| Lobular                 | 91 (12.3)                 | 5 (27.8)                      |         |
| Ductolobular            | 23 (3.1)                  | 0                             |         |
| Other                   | 44 (6.0)                  | 1 (5.6)                       |         |
| Tumour stage of invasive cancers, No (%) |                   |                               | 0.97    |
| T1                      | 569 (77.0)                | 14 (77.8)                     |         |
| T2+                     | 169 (22.9)                | 4 (22.2)                      |         |
| Unknown                 | 1 (0.1)                   | 0                             |         |
| Lymph node status of invasive cancers, No (%) |                   |                               | 0.7     |
| N+                      | 164 (22.2)                | 5 (27.8)                      |         |
| N-                      | 561 (76.0)                | 13 (72.2)                     |         |
| Unknown                 | 14 (1.9)                  | 0                             |         |
| Bloom & Richardson grade, No (%) |                   |                               | 0.8     |
| I                       | 329 (44.5)                | 8 (44.4)                      |         |
| II                      | 318 (43.0)                | 9 (50.0)                      |         |
| III                     | 87 (11.8)                 | 1 (5.6)                       |         |
| Unknown                 | 5 (0.7)                   | 0                             |         |
| Oestrogen receptor status, No (%) |                  |                               | 0.4     |
| Positive                | 667 (90.3)                | 18 (100)                      |         |
| Negative                | 69 (9.3)                  | 0                             |         |
| Unknown                 | 3 (0.4)                   | 0                             |         |
| Progesterone receptor status, No (%) |                  |                               | 0.5     |
| Positive                | 520 (70.4)                | 15 (83.3)                     |         |
| Negative                | 216 (29.2)                | 3 (16.7)                      |         |
| Unknown                 | 3 (0.4)                   | 0                             |         |
| Her2/Neu receptor status, No (%) |                  |                               | 0.8     |
| Positive                | 72 (9.7)                  | 1 (5.6)                       |         |
| Negative                | 663 (89.7)                | 17 (94.4)                     |         |
| Unknown                 | 4 (0.5)                   | 0                             |         |
| Final surgical treatment, No (%) |                  |                               | 0.9     |
| Breast conserving surgery | 726 (80.6)            | 17 (85.0)                     |         |
| Mastectomy              | 163 (18.1)                | 3 (15.0)                      |         |
| No surgery              | 11 (1.2)                  | 0                             |         |
| Unknown                 | 1 (0.1)                   | 0                             |         |

DCIS ductal carcinoma in situ
Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Dr. L.E.M. Duijm.

Conflict of interest The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry No complex statistical methods were necessary for this paper.

Ethical approval We have previously reported our screening studies, derived from our screening database, to the Medical Ethics Review Committee of the Catharina Hospital Eindhoven, the Netherlands (www.catharina-ziekenhuis.nl/metc/). This committee reviewed our studies and replied that according to the Medical Research Involving Human Subject Acts (WMO; www.cmo.nl) our kind of study does not need the approval of the committee.

Informed consent All women participating in the Dutch nationwide screening programme are asked to give informed consent to use their data for scientific and educational purposes. All women participating in our study had given this written informed consent.

Methodology

• prospective
• observational
• multi-centre study

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the license, and indicate if changes were made.

References

1. Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM et al (2017) The impact of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. Int J Cancer 141:671–677
2. Otto SJ, Fracheboud J, Loman CW et al (2003) Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:1411–1417
3. Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447
4. Pisano ED, Gatsonis C, Hendrick E et al (2005) Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773–1783
5. Bernardi D, Macaskill P, Pellegrini M et al (2016) Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol 17:1105–1113
6. Setz-Pels W, Duijm LE, Groenewoud JH et al (2011) Detection of bilateral breast cancer at biennial screening mammography in the Netherlands: a population-based study. Radiology 260:357–363
7. Waldherr C, Cerny P, Alternatt HJ et al (2013) Value of one-view breast tomosynthesis versus two-view mammography in diagnostic workup of women with clinical signs and symptoms and in women recalled from screening. AJR Am J Roentgenol 200:226–231
8. Lei J, Yang P, Zhang L, Wang Y, Yang K (2014) Diagnostic accuracy of digital breast tomosynthesis versus digital mammography for benign and malignant lesions in breasts: a meta-analysis. Eur Radiol 24:595–602
9. Gilbert FJ, Tucker L, Gillan MG et al (2015) The TOMMY trial: a comparison of TOMosynthesis with digital Mammography in the UK NHS Breast Screening Programme—a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess 19:i–xxiv 1–136
10. Lang K, Andersson I, Zackrisson S (2014) Breast cancer detection in digital breast tomosynthesis and digital mammography—a side-by-side review of discrepant cases. Br J Radiol 87:20140080
11. El Sharouni MA, Postma EL, Menezes GL et al (2016) High prevalence of MRI-detected contralateral and ipsilateral malignant findings in patients with invasive ductallobular breast cancer: impact on surgical management. Clin Breast Cancer 16:269–275
12. Brennan ME, Houssami N, Lord S et al (2009) Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 27:5640–5649
13. Wang SY, Long JB, Killelea BK et al (2016) Preoperative breast magnetic resonance imaging and contralateral breast occurrence among older women with breast cancer. J Clin Oncol 34:321–328
14. Duijm LE, Groenewoud JH, Jansen FH, Fracheboud J, van Beek M, de Koning HJ (2004) Mammography screening in the Netherlands: delay in the diagnosis of breast cancer after breast cancer screening. Br J Cancer 91:1795–1799
15. Sickles EA, D’Orsi CJ, Bassett LW et al (2013) ACR BI-RADS® Mammography. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. American College of Radiology
16. NABON (2012) Richtlijn Mammacarcinoom. Available via http://www.oncoline.nl/mammacarcinoom. Accessed 11 July 2017
17. Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678
18. Sobin LH, Gospodarowicz MK, Witkink C (eds) (2009) TNM classification of malignant tumours, 7th edn. Wiley, Chichester
19. Maes RM, Dronkers DJ, Hendriks JH, Thijssen MA, Nab HW (1997) Do non-specific minimal signs in a biennial mammographic breast cancer screening programme need further diagnostic assessment? Br J Radiol 70:34–38
20. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L (2008) European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document. Ann Oncol 19:614–622
21. McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF (2016) Effectiveness of digital breast tomosynthesis compared with digital mammography: outcomes analysis from 3 years of breast cancer screening. JAMA Oncol 2: 737–743
22. Lobbes MB, Lalji U, Houver J et al (2014) Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme. Eur Radiol 24:1668–1676
23. Lalji UC, Houben IP, Prevos R et al (2016) Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a large multireader, multicase study. Eur Radiol 26:4371–4379
van Breest Smallenburg V, Duijm LE, Voogd AC et al (2012) Lower sensitivity of screening mammography after previous benign breast surgery. Int J Cancer 130:122–128

O’Brien JA, Ho A, Wright GP et al (2015) Breast-conserving surgery in bilateral breast cancer. Ann Surg Oncol 22:3389–3396

Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750

Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197

Iacconi C, Galman L, Zheng J et al (2016) Multicentric cancer detected at breast MR imaging and not at mammography: important or not? Radiology 279:378–384

Melnikow J, Fenton JJ, Whitlock EP et al (2016) Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 164:268–278

Houssami N, Abraham LA, Onega T et al (2014) Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast. Breast Cancer Res Treat 145:765–773

Chandwani S, George PA, Azu M et al (2014) Role of preoperative magnetic resonance imaging in the surgical management of early-stage breast cancer. Ann Surg Oncol 21:3473–3480

Vriens IJH, Keymeulen K, Lobbes MBI et al (2017) Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. Eur J Cancer 81:74–80

Sprague BL, Stout NK, Schechter C et al (2015) Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med 162:157–166

Lee CI, Cevik M, Alagoz O et al (2015) Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 274:772–780

Provencher L, Hogue JC, Desbiens C et al (2016) Is clinical breast examination important for breast cancer detection? Curr Oncol 23: e332–e339